Yannick Auclair, Ph. D.

Scientifique principal

Yannick Auclair est titulaire d'un baccalauréat spécialisé en microbiologie et immunologie ainsi que d'un doctorat en biologie moléculaire obtenu à l'Université de Montréal en 2010.

Ses travaux de recherche doctorale portaient sur l'étude des mécanismes de maintien de la stabilité du génome, des travaux qui ont notamment été récompensés par le Prix de la meilleure thèse de doctorat en 2010 par la Faculté des études supérieures. Appuyé par une bourse du Fonds de recherche du Québec – Santé (FRSQ), M. Auclair a par la suite poursuivi un stage postdoctoral à l'Université McGill (département d'oncologie), où il a pu développer son expertise.

C'est en 2014 que M. Auclair devient professionnel scientifique en santé à l'INESSS. Il occupe présentement le poste de scientifique principal au Bureau - Méthodologies et éthique.

 
Date Title
09-29-2025 Access to breast cancer screening for Québec women aged 40 to 49: issues, considerations and implementation approach
08-20-2024 Evaluation of intensive behavioural intervention (EIBI) for preschool-age autistic children in Québec
02-13-2024 Reflection Guide Supporting Clinical and Organizational Practices in Rehabilitation Services for Young People with Adjustment Problems Aged 10 or Older
12-21-2023 Assessment of InterceptTM and MirasolTM Pathogen Reduction Technologies for the Treatment of Labile Blood Products in Quebec
09-18-2023 Implantable Medical Device Tracking Methods
06-16-2023 Evaluation and Implementation of Digital Health Solutions: A Look at User Participation
05-29-2023 Principles and Criteria for Gene Selection for the Molecular Diagnosis of Constitutional Genetic Diseases by Next-Generation Sequencing
09-16-2022 Next Generation Sequencing Hereditary Cancer Gene Panels
07-15-2022 Hereditary Cardiovascular diseases NGS Panel Evaluation report on the repatriation of an analysis carried out outside of the province of Québec
06-27-2022 Molecular profiling of adult solid tumors - Focus PanelTM (IlluminaTM) - 52 somatic biomarkers analysis
02-14-2022 Next-generation sequencing (NGS) panels for muscle disease
02-01-2022 Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT
01-23-2022 Evaluation of Synvisc™ and Synvisc One™ for the management of knee osteoarthritis
01-10-2022 Integration of Real-World Data and Evidence into Assessments to Support Decision-Making in the Pharmaceutical Sector
03-16-2021 HemlibraTM (emicizumab) - Hemophilia A without inhibitor (re evaluation) - March 2021
02-01-2021 Artificial intelligence-assisted diabetic retinopathy tele-screening
01-19-2021 Advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology
01-05-2021 Use of the SpaceOAR™ hydrogel rectal spacer during prostate radiotherapy
12-18-2020 Xen45 gel implant for micro-invasive glaucoma surgery (migs)
11-24-2020 Wound culture: relevance and indications
10-26-2020 Continuous glucose monitoring system (Guardian Connect®, Medtronic)
07-31-2020 Neonatal screening for nine inborn errors of metabolism
06-29-2020 RebinynTM (Nonacog beta pegol) - Coagulation factor IX (Recombinant)
04-08-2020 Flash glucose monitoring system (Freestyle libreTM, Abbott) (update april 8, 2020)
02-18-2020 The therapeutic value of hyperbaric oxygen (HBO) on children with cerebral palsy
02-17-2020 iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)
02-10-2020 Continuous glucose monitoring system (Dexcom G6MC Dexcom)
01-27-2020 Tomosynthesis and breast cancer: diagnostic evaluation and other uses
01-14-2020 VonvendiTM (vonicog alfa) recombinant von willebrand factor – von willebrand disease - Update list - January 2020
12-02-2019 HemlibraTM - Update to Québec’s list of blood products, December 2019
09-30-2019 AlphanateTM - Update to Québec list of blood products - September 2019

Subscribe to our newsletter now

Subscription